NP19 is a novel and potent inhibitor of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 (PD-1/PD-L1) Interaction with IC50 of 12 nM in homogeneous time-resolved fluorescence (HTRF) binding assays.

Evixapodlin(also known as PD-1/PD-L1-IN 7) is a programmed cell death ligand 1 (PD-L1) inhibitor.

Nivolumab (BMS-936558; ONO-4538; MDX-1106; Opdivo) is a programmed death receptor-1 (PD-1) blocking antibody, known also as therapeutic antibody of PD-1, that has been approved for use to treat advanced (metastatic) non-small cell lung cancer.

INCB-086550 (INCB-086550) is a novel, investigational and selective small molecule PD-1/PD-L1 inhibitor based on the biphenyl scaffold core structure first disclosed by BMS company.

BMS-1001 is a novel and potent PD-1/PD-L1 interaction inhibitor.

CA-170 (also known as AUPM170 or PD-1-IN-1) is a first-in-class, potent and orally available small molecule inhibitor of the immune checkpoint regulatory proteins PD-L1 (programmed cell death ligand-1), PD-L2 and VISTA (V-domain immunoglobulin (Ig) suppressor of T-cell activation (programmed death 1 homolog; PD-1H).

Fraxinellone is a naturally occurring anti-inflammatory agent isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus.

BMS-1166 HCl, the hydrochloride salt of BMS1166, is a novel and potent small molecule inhibitor of the PD-1/PD-L1 PPI/protein protein interaction with anticancer and immunomodulatory activity.

Sulfamethoxypyridazine (also known as CL13494) is a long-acting sulfonamide antibiotic for the treatment of dermatitis herpetiformis.

N-deacetylated BMS-202, the deacetylated product of BMS-202 (also known as PD1-PDL1 inhibitor 2, BMS 202, BMS202), is a inhibitor of the PD-1 (Programmed death- 1)/PD-Ll (Programmed death-ligand 1) protein/protein interaction with potential anticancer activities.